updates2.advancedpractitioner.com
Open in
urlscan Pro
23.100.15.180
Public Scan
Submitted URL: https://updates2.advancedpractitioner.com/
Effective URL: https://updates2.advancedpractitioner.com/cardio-oncology/
Submission: On October 05 via automatic, source certstream-suspicious — Scanned from DE
Effective URL: https://updates2.advancedpractitioner.com/cardio-oncology/
Submission: On October 05 via automatic, source certstream-suspicious — Scanned from DE
Form analysis 0 forms found in the DOM
Text Content
From the publishers of JADPRO Cardio-Oncology Updates . Select Category * Immune Checkpoint Inhibitors * Kinase Inhibitors * HER2-Targeted Therapies * Novel Immunotherapies (CAR-T, BiTE) * * Home * Class Categories * Immune Checkpoint Inhibitors * Kinase Inhibitors * HER2-Targeted Therapies * Novel Immunotherapies (CAR-T, BiTE) * Cardio-Oncology Basics * Meet the Faculty * Message from the Program Chair * Case Studies * Immune Checkpoint Inhibitors * Kinase Inhibitors * HER2-Targeted Therapies * Novel Immunotherapies (CAR-T, BiTE) * Fast Facts * Immune Checkpoint Inhibitors * Kinase Inhibitors * HER2-Targeted Therapies * Novel Immunotherapies (CAR-T, BiTE) * Videos * Resources * News & Literature Highlights * Visit JADPRO Online * Contact MESSAGE FROM THE PROGRAM CHAIR March 2021 Jessica Shank Coviello, DNP, APRN, ANP-BC Associate Professor of Nursing Yale University School of Nursing Did you know that our JADPRO Cardio-Oncology Updates website is full of resources and information to help you and your patients manage cancer treatment–related cardiotoxicities? Make sure to check out our real-world case studies, specially curated news and literature articles, treatment guidelines and recommendations, Fast Fact PDFs, and expert video series. All of our offerings are organized by drug class, so you can easily find helpful information on cardiotoxicities associated with HER2-targeted therapies, kinase inhibitors, immune checkpoint inhibitors, and novel immunotherapies. View All Messages Fast Facts -------------------------------------------------------------------------------- * Immune Checkpoint Inhibitors * Kinase Inhibitors * HER2-Targeted Therapies * Novel Immunotherapies (CAR-T, BiTE) News & Literature Highlights * Novel Immunotherapies Itacitinib (INCB039110), a JAK1 inhibitor, Reduces Cytokines Associated With Cytokine Release Syndrome Induced by CAR T-Cell Therapy Clinical Cancer Research -------------------------------------------------------------------------------- * Kinase Inhibitors Pooled Analysis of Cardiovascular Events From Clinical Trials Evaluating Acalabrutinib Monotherapy in Patients With Chronic Lymphocytic Leukemia (CLL) 2020 ASH Annual Meeting -------------------------------------------------------------------------------- * HER2-Targeted Therapies Deceleration Capacity of Heart Rate Predicts Trastuzumab‐Related Cardiotoxicity in Patients With HER2‐Positive Breast Cancer: A Prospective Observational Study Journal of Clinical Pharmacy and Therapeutics -------------------------------------------------------------------------------- * HER2-Targeted Therapies Cardioncological Approach for Trastuzumab Therapy in Breast Cancer Patients With Cardiotoxicity: Impact on Adherence and Clinical Outcome Frontiers in Pharmacology -------------------------------------------------------------------------------- * HER2-Targeted Therapies Mechanisms and Potential Interventions Associated With the Cardiotoxicity of ErbB2-Targeted Drugs: Insights From in vitro, in vivo, and Clinical Studies in Breast Cancer Patients Cellular and Molecular Life Sciences -------------------------------------------------------------------------------- View More Resources * General Cardio-Oncology The Cancer Patient and Cardiology -------------------------------------------------------------------------------- * General Cardio-Oncology The Role of Cardiovascular Imaging in Cancer Patients Receiving Cardiotoxic Therapies: A Position Statement on Behalf of the Heart Failure Association (HFA), the European Association of Cardiovascular Imaging (EACVI) and the Cardio‐Oncology Council of the European Society of Cardiology (ESC) -------------------------------------------------------------------------------- * General Cardio-Oncology Baseline Cardiovascular Risk Assessment in Cancer Patients Scheduled to Receive Cardiotoxic Cancer Therapies: A Position Statement and New Risk Assessment Tools From the Cardio-Oncology Study Group of the Heart Failure Association of the European Society -------------------------------------------------------------------------------- * General Cardio-Oncology NCCN Clinical Practice Guidelines in Oncology: Survivorship Version 2.2020 -------------------------------------------------------------------------------- * General Cardio-Oncology Cardiovascular and Cancer Risk: The Role of Cardio-Oncology -------------------------------------------------------------------------------- View More Class Categories * Immune Checkpoint Inhibitors -------------------------------------------------------------------------------- * Kinase Inhibitors -------------------------------------------------------------------------------- * HER2-Targeted Therapies -------------------------------------------------------------------------------- * Novel Immunotherapies (CAR-T, BiTE) CARDIO-ONCOLOGY BASICS -------------------------------------------------------------------------------- * What is Cardio-Oncology? -------------------------------------------------------------------------------- * Link Between Cancer, Treatment, and Heart Disease -------------------------------------------------------------------------------- * Cardio-Oncology Standards of Care -------------------------------------------------------------------------------- * CV Evaluation of Patients Before and During Cancer Therapy -------------------------------------------------------------------------------- * Cancer Treatment–Related Cardiotoxicity -------------------------------------------------------------------------------- * Breast Cancer Drugs and Cardiotoxicity -------------------------------------------------------------------------------- * Cardio-Oncology Basics: Conclusions MEET THE FACULTY Videos * Novel Immunotherapies Managing Cardiotoxicity Associated With BiTE Therapy: A Case Study -------------------------------------------------------------------------------- * HER2-Targeted Therapies Monitoring and Management Strategies for HER2-Targeted Therapy–Associated Cardiotoxicity -------------------------------------------------------------------------------- * Immune Checkpoint Inhibitors Managing Cardiotoxicity Associated With Immune Checkpoint Inhibitor Therapy -------------------------------------------------------------------------------- * Kinase Inhibitors Managing Ibrutinib-Associated Cardiotoxicity in CLL: A Case Study -------------------------------------------------------------------------------- * HER2-Targeted Therapies HER2-Targeted Therapies: Cardiotoxicity Incidence -------------------------------------------------------------------------------- View More This activity is supported by Bristol-Myers Squibb and Pharmacyclics LLC.